Skip to main content
Contact Us
Subscribe
E-Edition
48°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tharimmune, Inc. - Common Stock
(NQ:
THAR
)
2.070
-0.030 (-1.43%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tharimmune, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
December 16, 2024
Via
ACCESSWIRE
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
December 06, 2024
Via
ACCESSWIRE
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
November 27, 2024
Via
ACCESSWIRE
What's Going On With Tharimmune Shares Monday?
November 18, 2024
Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver...
Via
Benzinga
THAR Stock Earnings: Tharimmune Reported Results for Q2 2024
August 12, 2024
Tharimmune just reported results for the second quarter of 2024.
Via
InvestorPlace
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
November 18, 2024
Via
ACCESSWIRE
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
November 13, 2024
Via
ACCESSWIRE
10 Health Care Stocks Moving In Monday's Pre-Market Session
November 04, 2024
Via
Benzinga
Tharimmune Announces Upcoming Conference Presentations
November 04, 2024
Via
ACCESSWIRE
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
October 30, 2024
Via
Benzinga
Exposures
Fossil Fuels
S&P 500 Edges Lower; US Crude Oil Inventories Fall
October 30, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
What's Going On With Tharimmune Shares Wednesday?
October 30, 2024
Tharimmune, Inc. (NASDAQ:THAR) shares are moving higher on Wednesday after the company announced it received overall positive feedback from the European Medicines Agency (EMA) on its TH104 clinical...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 30, 2024
Via
Benzinga
Dow Surges Over 150 Points; Alphabet Posts Upbeat Results
October 30, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
October 30, 2024
Via
ACCESSWIRE
Tharimmune Announces Upcoming Conference Presentations
October 25, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
October 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 30, 2024
Via
Benzinga
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
September 30, 2024
Via
ACCESSWIRE
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
September 16, 2024
Via
ACCESSWIRE
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
July 22, 2024
Via
ACCESSWIRE
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
July 17, 2024
Via
ACCESSWIRE
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
July 16, 2024
Via
ACCESSWIRE
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
July 10, 2024
Via
ACCESSWIRE
Tharimmune Announces $2.08 Million Private Placement
June 20, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 17, 2024
Via
Benzinga
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
June 17, 2024
Via
ACCESSWIRE
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
June 10, 2024
Via
Benzinga
Why Tharimmune (THAR) Shares Are Getting Hammered
June 10, 2024
Tharimmune shares are trading lower by 30% during Monday's session. The company late Friday announced it had entered into an "at the market" offering agreement.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
